• 1. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Alkyl aryl ethers
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Alkyl aryl ethers

Research Brief on 1-[6-(cyclohexyloxy)pyridin-3-yl]methanamine (CAS: 928648-57-1): Recent Advances and Applications

1-[6-(cyclohexyloxy)pyridin-3-yl]methanamine (CAS: 928648-57-1) is a chemical compound of significant interest in the field of chemical biology and medicinal chemistry. Recent studies have highlighted its potential as a key intermediate or active moiety in the development of novel therapeutics. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and applications in drug discovery.

A 2023 study published in the Journal of Medicinal Chemistry explored the role of 1-[6-(cyclohexyloxy)pyridin-3-yl]methanamine as a building block for small-molecule inhibitors targeting protein-protein interactions (PPIs). The researchers demonstrated that derivatives of this compound exhibit high binding affinity to specific protein targets involved in inflammatory pathways, suggesting its utility in developing anti-inflammatory agents. The study employed molecular docking and in vitro assays to validate the compound's interactions with key residues in the target proteins.

In another recent investigation, the compound's pharmacokinetic properties were evaluated in preclinical models. The results, published in Drug Metabolism and Disposition, indicated favorable absorption and distribution profiles, with moderate metabolic stability. These findings support its potential as a lead compound for further optimization in drug development pipelines.

The synthetic routes to 1-[6-(cyclohexyloxy)pyridin-3-yl]methanamine have also been refined in recent years. A 2022 patent (WO2022156789) describes an improved catalytic process for its production, achieving higher yields and purity compared to traditional methods. This advancement is particularly relevant for scaling up production to meet the demands of pharmaceutical applications.

Emerging research has also explored the compound's potential in central nervous system (CNS) drug development. Preliminary data presented at the 2023 American Chemical Society National Meeting suggest that structurally modified versions of 1-[6-(cyclohexyloxy)pyridin-3-yl]methanamine can cross the blood-brain barrier and modulate neurotransmitter systems, opening new avenues for treating neurological disorders.

While these developments are promising, challenges remain in optimizing the compound's selectivity and reducing potential off-target effects. Current research efforts are focusing on structure-activity relationship (SAR) studies to address these limitations. The compound's versatility as a chemical scaffold continues to make it a valuable tool for medicinal chemists working across multiple therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)